Tumstatin转基因巨核细胞在NOD/SCID鼠体内产生抗新生血管作用血小板

Tumstatin transgenic megakaryocyte produce anti-angiogenesis platelet in NOD/SCID mice

目的了解tumstatin转基因巨核细胞在非肥胖糖尿病/重症联合免疫缺陷(NOD/SCID)鼠体内生成血小板情况及其抗新生血管作用。方法制备的tumstatin转基因巨核细胞注入NOD/SCID鼠体内,定期取血,通过流式细胞仪分析转基因血小板产生情况;激光共聚焦法检测血小板的tumstatin表达;内皮细胞管状结构形成试验检测血小板的抗血管生成作用;血小板聚集试验检测转基因血小板的聚集功能。结果 tumstatin转基因巨核细胞输注NOD/SCID鼠后的第3天,外周血可检测到人血小板;血小板表达tumstatin;这种转基因血小板可显著抑制内皮细胞管状结构形成并保持正常的聚集功能。结论 tumstatin转基因巨核细胞可在NOD/SCID鼠体内产生有抑制血管形成且保持正常聚集功能的血小板,为进一步抗肿瘤研究奠定基础。

Objective To investigate tumstatin transgenic megakaryocyte producing platelets in NOD/SCID mice and its anti-angiogenesis fuction. Methods Tumstatin transgenic megakaryocyte was injected into NOD/SCID mice, and mice peripheral blood was regularly taken. Flow tion; immunofluoreseence was used to test the expression of cytometry was used to test transgenic platelets produc- tumstatin; endothelial cells tubular structure formation test was used to sults After 3 d test anti - angiogenesis ruction; platelet aggregation test was used to test aggregation function. Re- of transgenic megakaryocyte infusion, human platelets could be detected in peripheral blood of NOD/SCID mice, and the tumstatin expression was observed in platelets, which could obviously inhibit the endo- thelial cells tubular structure formation and kept nomal aggregation function. Conclusion Tumstatin transgenic megakaryocyte can produce anti-angiogenesis platelets having normal aggregation function in NOD/SCID mice, which lays the foundation for further anti-tumor research.